Trinity Biotech (TRIB)

Executive Summary

Trinity Biotech is a publicly traded Irish diagnostics company that develops, manufactures, and markets clinical diagnostic products and supplies raw materials to the life sciences industry. With a focus on infectious disease, autoimmune, and diabetes testing, the company has built a diversified portfolio of reagents, kits, and instruments. Despite its small market capitalization (~$12M), Trinity Biotech maintains a global presence, distributing products in over 80 countries. The company has faced revenue headwinds in recent years due to competitive pressures and a shift toward point-of-care testing, but it continues to invest in innovation and operational efficiency to stabilize its top line. Looking ahead, Trinity Biotech is focusing on expanding its point-of-care offerings and leveraging its raw materials supply business to drive growth. The company has streamlined its cost structure and is pursuing strategic partnerships to broaden its product reach. While profitability remains a challenge, management’s emphasis on high-margin consumables and potential new product launches could improve financial performance. Key upcoming catalysts include the launch of a novel point-of-care diagnostic test, potential FDA clearance for a new assay, and a distribution partnership that could expand market access. These initiatives, if successful, may help the company regain investor confidence and achieve sustainable growth.

Upcoming Catalysts (preview)

• Q3 2026Launch of new point-of-care diagnostic test60% success
• Q4 2026FDA approval for a new infectious disease assay50% success
• H1 2027Strategic distribution partnership with a major healthcare distributor40% success